Beta Bionics
BBNX
18.08
-0.55
-2.95%
Beta Bionics
US · BBNX
#3406 by market cap
Listed 2025
18.08
-0.55
-2.95%
Live - 5344 symbols - heartbeat 272s ago
· 2026-10-08 09:16
Pre-market
17.85
-1.27%
After-hours
18.08
0.00%
- Market cap
- 813.41M
- P/E (TTM)i
- -11.15
- P/Bi
- 3.17
- EPSi
- -1.65
- Div yieldi
- 0.00%
- 52W posi
- 39%
Reader sentiment
Are you bullish or bearish on BBNX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 10.74, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 4 years
Latest year +53.94% YoY
Margins
- Gross margin
- 55.40%
- Operating margin
- -71.50%
- Net margin
- -73.02%
Key ratios & quality
- Altman Z-Scorei
- 10.74
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 179.00K | 12.00M | 65.12M | 100.25M |
| Gross profit | 179.00K | 6.31M | 35.89M | 55.54M |
| Selling & admin expenses | 34.60M | 24.22M | 54.96M | 92.43M |
| Research & development | 31.43M | 17.94M | 26.18M | 34.79M |
| Operating profit | -65.84M | -35.85M | -45.25M | -71.68M |
| Pretax profit | -64.75M | -44.10M | -54.76M | -73.20M |
| Tax | -- | -- | -- | -- |
| Net profit | -64.75M | -44.10M | -54.76M | -73.20M |
| Basic EPS | -2 | -1 | -1 | -2 |
| Diluted EPS | -2.12 | -1.45 | -1.28 | -1.81 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 17.64M | 23.24M | 27.25M | 32.12M | 27.63M | 32.01M |
| Gross profit | 8.97M | 12.50M | 15.12M | 18.94M | 16.44M | 18.90M |
| Selling & admin expenses | 20.02M | 23.50M | 23.97M | 24.94M | 30.35M | 34.24M |
| Research & development | 7.59M | 8.87M | 8.20M | 10.13M | 10.36M | 10.24M |
| Operating profit | -18.64M | -19.87M | -17.04M | -16.12M | -24.27M | -25.58M |
| Pretax profit | -28.66M | -16.87M | -14.21M | -13.47M | -21.90M | -23.40M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -28.66M | -16.87M | -14.21M | -13.47M | -21.90M | -23.40M |
| Basic EPS | -1 | 0 | 0 | 0 | 0 | -1 |
| Diluted EPS | -0.93 | -0.39 | -0.33 | -0.30 | -0.49 | -0.53 |
Balance sheet
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total current assets | 28.47M | 103.62M | 132.92M | 267.91M |
| Cash & ST investments | 27.68M | 96.75M | 103.58M | 219.13M |
| Inventory | 0 | 1.25M | 13.32M | 21.72M |
| Total assets | 35.53M | 110.04M | 149.65M | 328.74M |
| Total current liabilities | 8.87M | 10.61M | 21.15M | 30.92M |
| Short-term debt | 976.00K | 1.22M | 1.53M | 1.94M |
| Long-term debt | -- | -- | -- | -- |
| Total liabilities | 205,561,000.00 | 313,145,000.00 | 395,005,000.00 | 41,133,000.00 |
| Total equity | -170.03M | -203.11M | -245.36M | 287.61M |
| Retained earnings | -185.57M | -229.66M | -296.74M | -369.94M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 261.92M | 286.08M | 270.03M | 267.91M | 247.99M | 231.03M |
| Cash & ST investments | 231.47M | 249.72M | 228.69M | 219.13M | 199.52M | 180.49M |
| Inventory | 15.73M | 17.32M | 20.37M | 21.72M | 23.73M | 23.92M |
| Total assets | 338.02M | 329.97M | 330.05M | 328.74M | 304.42M | 292.39M |
| Total current liabilities | 16.49M | 19.49M | 25.39M | 30.92M | 23.19M | 26.02M |
| Short-term debt | 1.52M | 1.52M | 1.98M | 1.94M | 1.84M | 1.59M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 24,272,000.00 | 28,338,000.00 | 35,286,000.00 | 41,133,000.00 | 33,172,000.00 | 36,021,000.00 |
| Total equity | 313.75M | 301.63M | 294.76M | 287.61M | 271.25M | 256.37M |
| Retained earnings | -325.39M | -342.26M | -356.47M | -369.94M | -391.83M | -415.24M |
Cash flow
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating cash flow | -60.21M | -32.45M | -48.27M | -50.93M |
| Depreciation & amortization | 2.09M | 2.09M | 2.28M | 2.88M |
| Free cash flow | -60.98M | -32.85M | -51.67M | -56.22M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 0 | 210.12M |
| Ending cash balance | 27.78M | 26.67M | 30.53M | 31.68M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -19.98M | -13.59M | -8.73M | -8.63M | -23.83M | -14.62M |
| Depreciation & amortization | 604.00K | 653.00K | 683.00K | 935.00K | 987.00K | 1.12M |
| Free cash flow | -20.31M | -15.37M | -10.01M | -10.53M | -25.21M | -15.66M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 211.02M | 0 | 0 | -904.00K | 0 | 0 |
| Ending cash balance | 42.55M | 35.18M | 38.59M | 31.68M | 30.31M | 44.42M |
Returns & efficiency
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| ROE %i | -- | -- | -- | -346.51 |
| ROA %i | -182.26 | -60.59 | -42.17 | -30.60 |
| ROIC %i | -- | -- | -- | -296.20 |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -36,165.92 | -367.08 | -69.48 | -71.50 |
| FCF / sales %i | -- | -- | -- | -- |
| Current ratioi | 3.21 | 9.77 | 6.29 | 8.66 |
| Quick ratioi | 3.12 | 9.54 | 5.51 | 7.73 |
| Debt / assetsi | 11.63 | 3.84 | 4.85 | 2.22 |
| LT debt / equityi | -- | -- | -- | 1.87 |
| Interest coveragei | -4,624.07 | -647.51 | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 724.29 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -22.62 | -24.32 | -236.20 | -346.51 | -22.71 | -26.16 |
| ROA %i | -20.99 | -22.24 | -36.46 | -30.60 | -20.68 | -23.45 |
| ROIC %i | -23.75 | -26.14 | -215.24 | -296.20 | -25.82 | -29.07 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -77.96 | -80.14 | -77.16 | -71.50 | -70.13 | -69.75 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 15.88 | 14.68 | 10.64 | 8.66 | 10.69 | 8.88 |
| Quick ratioi | 14.70 | 13.50 | 9.57 | 7.73 | 9.39 | 7.72 |
| Debt / assetsi | 2.06 | 2.03 | 2.33 | 2.22 | 2.27 | 2.23 |
| LT debt / equityi | 1.74 | 1.71 | 1.94 | 1.87 | 1.87 | 1.92 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Single-use products is the largest reported line at 59.79% of revenue, across 2 reported segments.
- iLet follows at 40.21%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Single-use products59.79%
iLet40.21%
Quote time 2026-10-08 09:16:15 · For reference only, not investment advice and not tailored to your situation.